Billionaire Buys Stake In Gene Therapy Stock
Ultragenyx may not have crossed your radar but it’s already in billionaire Stan Druckenmiller’s portfolio. What has he spotted in this novel therapies for rare and ultra-rare genetic diseases firm that convinced him to take a position?
Its focus on underserved patient populations, deep pipeline of innovative products, and strong track record in obtaining regulatory approvals make it an attractive long-term investment, » Read more about: Billionaire Buys Stake In Gene Therapy Stock »
Read More
Market Commentary: Is $1 Billion A Year Enough?
Imagine I could reveal to you a stock that generates a cool $1 billion of income a year on revenues of $4.4 billion? That’s right a company that is so profitable it regularly reports 10-figures of profits, and now what if I told you the market values it at less than 1x sales, would you be interested?
» Read more about: Market Commentary: Is $1 Billion A Year Enough? »
Read More
Market Commentary: 1 Marine Stock On Sale
Buying a boat manufacturer ranks right up there as one of the most treacherous investments when interest rates are elevated, at least on the surface.
But then there’s Marine Products Corporation that trades with a price-to-earnings ratio of just 7x. Not only is the PE ratio attractive but the earnings have been growing steadily quarter over quarter and operating income looks very attractive for the past three years too.
» Read more about: Market Commentary: 1 Marine Stock On Sale »
Read More
Market Commentary: 1 Pet Stock You Would Be Barking Mad To Overlook
Following a market correction in 2022 of about 20%, this year has been topsy turvy with some stocks doubling and others lagging like an anchor is tied to their share price.
PetMed Express falls into that latter category as losses mounted but the underwhelming performance has created a potential opening for value investors to get in at really low prices.
» Read more about: Market Commentary: 1 Pet Stock You Would Be Barking Mad To Overlook »
Read More
1 Rare Stock Buffett Is Buying
Warren Buffett has spent 2024 stockpiling cash, even going so far as to sell off sizeable pieces of some of his largest investments. Recently, though, Berkshire Hathaway announced that it had made some modest acquisitions, including the addition of nearly 388,000 shares of domain name registry service Verisign (NASDAQ:VRSN).
These purchases brought Berkshire Hathaway’s holdings in Verisign to 13.2 million shares,
» Read more about: 1 Rare Stock Buffett Is Buying »
Read MoreThe Ivy
Breaking the $1 Billion Barrier, What’s Next for Security Leader?
CyberArk Software (NASDAQ: CYBR) just delivered a standout quarter, officially surpassing $1 billion in annual revenue for the first time in fiscal 2024. The identity security powerhouse—best known for its privileged access management solutions—is scaling at an impressive pace, fueled by surging demand, strategic acquisitions, and a seamless transition to a subscription-based model.
We take a deep dive into CyberArk’s latest earnings,
» Read more about: Breaking the $1 Billion Barrier, What’s Next for Security Leader? »
Read MoreThe Spotlight
Hyper Rich Politician Buys A Boatload Of..
Nancy Pelosi is among the highest earners in Congress with a salary of $223,000 yet her stock portfolio has grabbed the attention of watchers for its performance relative to the market and size.
Her portfolio has some grown to an astonishing $223 million. In the words of one X user, what started as a mockery,
» Read more about: Hyper Rich Politician Buys A Boatload Of.. »
Read MoreThe Daily
The Markets Mirror: S&P 500 sets new records: Resilient rally pushes index to 8.28% YTD gains
Last week, I reported on the S&P 500 slipping from record highs in the wake of political uncertainty surrounding possible changes in Federal Reserve leadership (“S&P 500 slips from Record highs as Trump moves closer to firing Fed chair Powell”).
At that point, the market wavered as investors processed both solid economic data and the unpredictable impact of breaking news.